Caris Life Sciences Launch of Caris Detect Multi-Cancer Early Detection Blood Test

Caris Life Sciences has launched its new multi-cancer early detection (MCED) blood test, 'Caris Detect', supported by positive data from its Achieve 1 study. Goldman Sachs maintains a 'Buy' rating with a $27 price target, citing significant TAM expansion potential.

Key Takeaways

• 1.Caris Life Sciences launched Caris Detect, an MCED blood test utilizing WGS, WTS, and AI.
• 2.The test features a list price of $3,500 and achieved 60.3% sensitivity (stage I/II) in the Achieve 1 clinical study.
• 3.Goldman Sachs maintains a Buy rating on CAI with a 12-month price target of $27.

Table of Contents

• Caris Life Sciences Inc. (CAI): Launch of Caris Detect, Multi-Cancer Early Detection Blood Test
• Exhibit 1: Caris's Potential Test Volume TAM Expansion from Pipeline
• Disclosure Appendix
• Reg AC
• GS Factor Profile
• M&A Rank
• Quantum
• Disclosures
• Company-specific regulatory disclosures
• Distribution of ratings/investment banking relationships
• Target price history table(s)
• Regulatory disclosures
• Disclosures required by United States laws and regulations
• Additional disclosures required under the laws and regulations of jurisdictions other than the United States
• Ratings, coverage universe and related definitions
• Global product; distributing entities
• General disclosures

Document Preview

Page 1 of 5

Subscribe for full accessStart Free Trial